The role of lymphatic transport in enhancing oral protein and peptide drug delivery
- PMID: 12455465
- DOI: 10.1081/ddc-120014573
The role of lymphatic transport in enhancing oral protein and peptide drug delivery
Abstract
The gastrointestinal lymphatic system is a specific transport pathway through which dietary lipids, fat-soluble vitamins, and water-insoluble peptide-type molecules (e.g., cyclosporine A) can gain access to the systemic circulation. Drugs transported by way of the gastrointestinal lymphatic system bypass the liver and avoid potential hepatic first-pass metabolism. Lymphatic delivery of immunomodulatory and low therapeutic index protein and peptide drugs used in the treatment of cancer cell metastases and HIV presents an opportunity to maximize therapeutic benefit while minimizing general systemic drug exposure. Furthermore, lymphatic drug transport may promote drug incorporation into the body's lipid-handling system, thus offering the potential to manipulate drug distribution and residence time within the body. This review article will discuss the potential utilization of lymphatic transport in enhancing the oral absorption of protein- and peptide-like drugs.
Similar articles
-
Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update.Adv Drug Deliv Rev. 2008 Mar 17;60(6):702-16. doi: 10.1016/j.addr.2007.09.007. Epub 2007 Nov 7. Adv Drug Deliv Rev. 2008. PMID: 18155316 Free PMC article. Review.
-
Intestinal transport as a potential determinant of drug bioavailability.Curr Clin Pharmacol. 2013 Aug;8(3):247-55. doi: 10.2174/1574884711308030012. Curr Clin Pharmacol. 2013. PMID: 23343017 Free PMC article. Review.
-
Lipid-Based Nanocarriers for Lymphatic Transportation.AAPS PharmSciTech. 2019 Jan 23;20(2):83. doi: 10.1208/s12249-019-1293-3. AAPS PharmSciTech. 2019. PMID: 30673895 Review.
-
Intestinal lymphatic transport for drug delivery.Adv Drug Deliv Rev. 2011 Sep 10;63(10-11):923-42. doi: 10.1016/j.addr.2011.05.019. Epub 2011 Jun 13. Adv Drug Deliv Rev. 2011. PMID: 21689702 Free PMC article. Review.
-
Targeting the intestinal lymphatic system: a versatile path for enhanced oral bioavailability of drugs.Expert Opin Drug Deliv. 2018 Aug;15(8):787-804. doi: 10.1080/17425247.2018.1503249. Epub 2018 Jul 26. Expert Opin Drug Deliv. 2018. PMID: 30025212 Review.
Cited by
-
Quantifying exploratory low dose compounds in humans with AMS.Adv Drug Deliv Rev. 2011 Jun 19;63(7):518-31. doi: 10.1016/j.addr.2010.10.009. Epub 2010 Oct 31. Adv Drug Deliv Rev. 2011. PMID: 21047543 Free PMC article. Review.
-
Nanoparticulate Drug Delivery Strategies to Address Intestinal Cytochrome P450 CYP3A4 Metabolism towards Personalized Medicine.Pharmaceutics. 2021 Aug 16;13(8):1261. doi: 10.3390/pharmaceutics13081261. Pharmaceutics. 2021. PMID: 34452222 Free PMC article. Review.
-
Effects of lipid-based oral formulations on plasma and tissue amphotericin B concentrations and renal toxicity in male rats.Antimicrob Agents Chemother. 2003 Oct;47(10):3339-42. doi: 10.1128/AAC.47.10.3339-3342.2003. Antimicrob Agents Chemother. 2003. PMID: 14506053 Free PMC article.
-
Lipid Drug Carriers for Cancer Therapeutics: An Insight into Lymphatic Targeting, P-gp, CYP3A4 Modulation and Bioavailability Enhancement.Adv Pharm Bull. 2020 Sep;10(4):524-541. doi: 10.34172/apb.2020.064. Epub 2020 Aug 9. Adv Pharm Bull. 2020. PMID: 33072532 Free PMC article. Review.
-
The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen.Pharm Res. 2005 May;22(5):728-35. doi: 10.1007/s11095-005-2588-5. Epub 2005 May 17. Pharm Res. 2005. PMID: 15906167 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical